WY 14,643 inhibits human aldose reductase activity

References

• Tomlinson DR, Stevens EJ, Diemel LT. Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol Sci. 1994; 15: 293–297
   PubMed Web of Science ®Google Scholar
• Gabbay KH. The sorbitol pathway and the complications of diabetes. N Engl J Med. 1973; 288: 831–836
   PubMed Web of Science ®Google Scholar
• Jaspan J. Pharmacological inhibition of aldose reductase in human diabetic neuropathy. Drugs 1986; 32(Suppl 2)23–29
   PubMedGoogle Scholar
• Brankston ER, Corriveau R, Laroche C, Roy R, Savard C, Roy D, Kelly R, Forget P, Rivard M, Boulerice F. Effect of AR inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. Clin Drug Invest. 1998; 15: 111–121
   Google Scholar
• Hodgkinson AD, Sondergaard KL, Yang B, Cross DF, Millward BA, Demaine AG. Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy. Kidney Int. 2001; 60: 211–218
   Google Scholar
• Galvez AS, Ulloa JA, Chiong M, Criollo A, Eisner V, Barros LF, Lavandero S. Aldose reductase induced by hyperosmotic stress mediates cardiomyocyte apoptosis: Differential effects of sorbitol and mannitol. J Biol Chem. 2003; 278: 38484–38494
   PubMedGoogle Scholar
• Morrison AD, Clements RS, Jr, Travis SB, Oski F, Winegrad AI. Glucose utilization by the polyol pathway in human erythrocytes. Biochem Biophys Res Commun. 1970; 40: 199–205
   PubMed Web of Science ®Google Scholar
• Gonzalez RG, Barnett P, Aguayo J, Cheng HM, Chylack LT, Jr. Direct measurement of polyol pathway activity in the ocular lens. Diabetes 1984; 33: 196–199
   PubMed Web of Science ®Google Scholar
• Kicic E, Palmer TN. Increased white cell aldose reductase mRNA levels in diabetic patients. Diabetes Res Clin Pract. 1996; 33: 31–36
   PubMed Web of Science ®Google Scholar
• Kinoshita JH, Nishimura C. The involvement of aldose reductase in diabetic complications. Diabetes Metab Rev. 1988; 4: 323–337
   PubMed Web of Science ®Google Scholar
• Pugliese G, Tilton RG, Williamson JR. Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab Rev. 1991; 7: 35–59
   PubMed Web of Science ®Google Scholar
• Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest. 1994; 94: 771–778
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes 1997; 46: 292–300
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Trueblood N, Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol. 1998; 275: H195–H203
   PubMed Web of Science ®Google Scholar
• Oates PJ, Mylari BL. Aldose reductase inhibitors: Therapeutic implications for diabetic complications. Expert Opin Investig Drugs 1999; 8: 2095–2119
   PubMedGoogle Scholar
• Young LH, Russell RR, Chyun DA, Ramahi T. In Diabetes and Cardiovascular Disease. Humana Press, Totowa, NJ 2001; 281–298, Totowa, NJ
   Google Scholar
• Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The framingham study. Am J Cardiol. 1974; 34: 29–34
   PubMed Web of Science ®Google Scholar
• Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557–1562
   PubMed Web of Science ®Google Scholar
• Jaffe AS, Spadaro JJ, Schechtman K, Roberts R, Geltman EM, Sobel BE. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J. 1984; 108: 31–37
   PubMed Web of Science ®Google Scholar
• Nesto RW, Zarich S. Acute myocardial infarction in diabetes mellitus: Lessons learned from ACE inhibition. Circulation 1998; 97: 12–15
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248–254
   PubMed Web of Science ®Google Scholar
• Nishimura C, Yamaoka T, Mizutani M, Yamashita K, Akera T, Tanimoto T. Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system. Biochim Biophys Acta. 1991; 1078: 171–178
   PubMed Web of Science ®Google Scholar
• Liu SQ, Bhatnagar A, Srivastava SK. Does sorbinil bind to the substrate binding site of aldose reductase?. Biochem Pharmacol 1992; 44: 2427–2429
   PubMed Web of Science ®Google Scholar
• Balendiran GK, Rajkumar B. Fibrates inhibit aldose reductase activity in the forward and reverse reactions. Biochem Pharmacol. 2005; 70: 1653–1663
   Google Scholar
• Tracey WR, Magee WP, Ellery CA, MacAndrew JT, Smith AH, Knight DR, Oates PJ. Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury. Am J Physiol Heart Circ Physiol. 2000; 279: H1447–H1452
   Google Scholar
• Hwang YC, Sato S, Tsai JY, Yan S, Bakr S, Zhang H, Oates PJ, Ramasamy R. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J. 2002; 16: 243–245
   PubMed Web of Science ®Google Scholar
• Trueblood N, Ramasamy R. Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am J Physiol. 1998; 275: 75–83
   Google Scholar
• Trueblood NA, Ramasamy R, Wang LF, Schaefer S. Niacin protects the isolated heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2000; 279: H764–H771
   PubMed Web of Science ®Google Scholar
• Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res. 1997; 33: 243–257
   PubMed Web of Science ®Google Scholar
• Taegtmeyer H, King LM, Jones BE. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Am J Cardiol. 1998; 82: 54K–60K
   Google Scholar
• Kagaya Y, Kanno Y, Takeyama D, Ishide N, Maruyama Y, Takahashi T, Ido T, Takishima T. Effects of long-term pressure overload on regional myocardial glucose and free fatty acid uptake in rats. A quantitative autoradiographic study. Circulation 1990; 81: 1353–1361
   Google Scholar
• Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol. 1994; 267: H742–H750
   Google Scholar
• Doenst T, Goodwin GW, Cedars AM, Wang M, Stepkowski S, Taegtmeyer H. Load-induced changes in vivo alter substrate fluxes and insulin responsiveness of rat heart in vitro. Metabolism 2001; 50: 1083–1090
   Google Scholar
• Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000; 10: 238–245
   PubMed Web of Science ®Google Scholar
• Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem. 1998; 273: 5678–5684
   PubMed Web of Science ®Google Scholar
• Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 2002; 16: 1027–1040
   PubMed Web of Science ®Google Scholar